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Simple Summary: Pancreatic cancer (PDAC) is a deadly disease, exacerbated by obesity, which
lacks effective therapeutic interventions. Most PDAC has a limited response to immune- and
chemotherapy. Treating PDAC is made additionally challenging by the rapid emergence of muscle
wasting and cachexia, which predict poor response to several therapies. We have found that dietary
supplementation with β-hydroxy-β-methylbutyrate promotes immunosurveillance in PDAC tumors
and protects muscle. This dietary supplement has the potential to be an important adjuvant in PDAC
therapy, opening the doors to immunotherapy response.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
deaths in the United States, and effective therapies for PDAC are currently lacking. Moreover,
PDAC is promoted and exacerbated by obesity, while cachexia and sarcopenia are exceptionally
common comorbidities that predict both poor survival and treatment response. Managing PDAC
with immunotherapies has thus far proven ineffective, partly due to the metabolically hostile tumor
microenvironment. β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine commonly used as
a dietary supplement to boost muscle growth and immune function, may be an attractive candidate
to augment PDAC therapy. We therefore sought to test the hypothesis that HMB would enhance
antitumor immunity while protecting mouse muscle mass. Control and diet-induced obese C57BL/6
male mice bearing subcutaneously injected Panc02 tumors were supplemented with 1% HMB
and treated with or without 50 mg/kg gemcitabine (n = 15/group). HMB was associated with
reduced muscle inflammation and increased muscle fiber size. HMB also reduced tumor growth
and promoted antitumor immunity in obese, but not lean, mice, independent of the gemcitabine
treatment. Separately, in lean tumor-bearing mice, HMB supplementation promoted an anti-PD1
immunotherapy response (n = 15/group). Digital cytometry implicated the decreased abundance of
M2-like macrophages in PDAC tumors, an effect that was enhanced by anti-PD1 immunotherapy.
We confirmed that HMB augments M1-like macrophage (antitumor) polarization. These preclinical
findings suggest that HMB has muscle-sparing and antitumor activities against PDAC in the context
of obesity, and that it may sensitize otherwise nonresponsive PDAC to immunotherapy.
Keywords: β-hydroxy-β-methylbutyrate; obesity; pancreatic cancer; immunotherapy
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated deaths in the United States. This high mortality rate is exacerbated by the limited
efficacy of chemotherapies and immunotherapies [1]. The immunotherapy response is
heavily regulated by metabolic features of the tumor microenvironment (TME), such as
hypoxia and acidity [2,3]. Thus, interventions to support antitumor immunity are critical if
immunotherapy is to become effective in PDAC.
Cancer-associated cachexia, defined by involuntary weight loss and breakdown of
adipose and muscle tissue, is present in about 80% of patients with pancreatic cancer
and contributes significantly to PDAC mortality [4,5]. Further, sarcopenia and cachexia
predict a poor response to immune checkpoint inhibition [6]. Obesity promotes chronic
inflammation and immune cell dysfunction [7], and the development and progression of
PDAC [8]. A growing proportion of patients with pancreatic cancer are obese at the start of
therapy, and many of these individuals have sarcopenic obesity, a condition characterized
by the presence of a high fat mass but a low muscle mass. Obesity in the presence of
sarcopenia is predictive of morbidity and mortality in patients with pancreatic cancer [9], at
least in part because sarcopenic obesity increases the risk of developing cancer cachexia [10].
Preclinical data showed that diet-induced obesity (DIO) promotes PDAC growth [11] and
sarcopenia [12] in mice. Obesity is also a critical regulator of the immunotherapy response
in some models, promoting an increased response to immune checkpoint blockade [13–16]
and increased toxicity to IL-2 anti-CD40 therapy [17].
β-hydroxy-β-methylbutyrate (HMB), a metabolite of the branched-chain amino acid
leucine, is emerging as a strong candidate for increasing muscle mass [18]. HMB supplementation increases muscle growth through activation of the mechanistic target of
rapamycin (mTOR) in muscle [19] and attenuates muscle protein degradation through the
prevention of nuclear factor-κB (NF-κB) activation [20]. HMB promotes improved function
of ex vivo macrophages and monocytes [21,22], but the effects of HMB supplementation
on PDAC growth are unknown, particularly in the context of obesity and immunotherapy.
Tumor necrosis factor alpha (TNFα) signaling through NF-kB is a pleotropic regulator
of the immunotherapy response [23]. NF-κB activation by cytokines such as TNFα is
pro-tumorigenic in PDAC, and inhibition of NF-κB reduces PDAC growth in mice [24]. In
muscle tissue, NF-κB activation leads to muscle atrophy via increased protein degradation [25]. Inhibition of NF-κB prevents cancer-induced muscle atrophy [26].
Given that muscle wasting is a critical feature of PDAC-associated morbidity and is exacerbated by obesity, new intervention strategies that both suppress PDAC progression and
preserve muscle mass in patients with pancreatic cancer and comorbid obesity are urgently
needed. Furthermore, interventions that promote a response to immunotherapy while
reducing muscle inflammation and can be safely administered may provide a tractable
approach to achieve this aim. Herein, we tested the hypothesis that immunomodulation by
HMB supplementation supports antitumor immunity, while preserving muscle mass, and
found that HMB has muscle-sparing and antitumor activities against PDAC in obese mice.
Moreover, our preclinical studies indicated that HMB sensitizes PDAC to immunotherapy.
2. Materials and Methods
2.1. Mice and Dietary Interventions
All experiments were approved by the Institutional Animal Care and Use Committee
at the University of Texas at Austin or the University of North Carolina at Chapel Hill.
Study 1 determined the effect of diet-induced obesity (DIO) and HMB supplementation
on PDAC tumor growth. Study 2 determined the effect of HMB supplementation on antiprogramed death 1 (PD1) immunotherapy response. Male C57BL/6 mice were obtained
from Charles River Breeding Laboratories at 6 to 8 weeks of age. Mice were placed on the
control diet and allowed to acclimate for 1 week. For Study 1, mice were randomized to
either continue on the control diet with 10% kcal from fat (D12450J from Research Diets) or
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receive the DIO diet with 60% kcal from fat (D12491 from Research Diets) for 10 weeks ad
libitum. For Study 2, all mice were provided with the AIN-93G (D10012G) diet ad libitum.
All diets were purchased from Research Diets, Inc (New Brunswick, NJ, USA). CaHMB (HMB) was incorporated at 1% (w/w) of the diet to achieve a daily fed amount
of ~0.5 g HMB/kg bodyweight (approximating a 6 g/day human dose [27]). For Study
1, dietary HMB supplementation began 2 days prior to tumor cell injection. Specifically,
mice (n = 30/group) were randomized to receive a control diet (D12450J), control + HMB,
DIO (D12491), or DIO + HMB. For Study 2, which also used 30 mice/diet group, HMB
supplementation began 1 week prior to tumor cell injection, with mice randomized to
receive either the control diet (which was AIN-93G for this study) or control + HMB.
2.2. Fasting Blood Glucose and Serum Collection
At week 10 on the diet for Study 1, all mice (n = 30/diet group) were fasted for
6 h and then blood was collected via tail nicks to assess fasting blood glucose levels
as measured with a Contour glucometer (Bayer HealthCare LLC, Whippany, NJ, USA).
This was repeated immediately prior to euthanasia. Blood was also collected prior to
tumor injections via retro-orbital bleeds and incubated at room temperature for 30 min
to coagulate, and were then centrifuged at 11,000 RCF for 5 min. Serum was separated,
snap-frozen, and stored at −80 ◦ C until used to measure circulating hormone levels.
2.3. Subcutaneous Panc02 Tumor Cell Injections
At the point of diet switch, all mice were subcutaneously injected into the right
flank with 250,000 Panc02 murine PDAC cells in PBS (generously provided by Dr. J.
Schlom, National Cancer Institute, Bethesda, MD, USA). Beginning 1 week after tumor cell
injections, tumors were measured biweekly with calipers.
2.4. Gemcitabine Treatment
In Study 1, once the tumors were palpable, all mice received either gemcitabine
(50 mg/kg) or vehicle injections intraperitoneally every 3 days. At week 15, all mice were
fasted for 6–8 h and then euthanized by CO2 inhalation followed by cervical dislocation.
2.5. Anti-PD1 Treatment
In Study 2, once the tumors were palpable, all mice received either anti-PD1 or isotype
control (200 µg/mouse) injections intraperitoneally every 3 days. After 3 weeks, all mice
were then euthanized by CO2 inhalation followed by cervical dislocation.
2.6. Tissue Harvest
Once tumors reached 1.5 cm in any direction in any group, all remaining mice were
euthanized. Tumors and gastrocnemius muscles were harvested and either snap-frozen in
liquid nitrogen and stored at −80 ◦ C, or fixed with 10% neutral-buffered formalin for 48 h
before paraffin embedding.
2.7. Cell Culture
Panc02 cells were cultured in DMEM supplemented with 10% FBS and 2 mM glutamine (Thermo Scientific, Waltham, MA, USA). All cell lines were negative when tested for
mycoplasma using the Universal Mycoplasma Detection Kit (ATCC, Manassas, VA, USA).
C2C12 cells (generously provided by Dr. E. Mills at the University of Texas at Austin)
were maintained in culture at <70% confluence in DMEM supplemented with 20% FBS
and 2 mM glutamine. For the differentiation experiments, C2C12 cells were seeded at 90%
confluence. After 18 h, the medium was removed and replaced with DMEM supplemented
with 2% horse serum (Sigma, St. Louis, MO, USA) and 2 mM glutamine. The medium was
replaced every second day for 6 days and then C2C12 cells were examined morphologically
for myotube formation. For the 18 h serum starvation experiments, C2C12 cells were
cultured using DMEM supplemented only with 2 mM glutamine and treated with or
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without HMB (4 mM) (Sigma, St. Louis, MO, USA) and TNFα (10 ng/mL) (Peprotech,
Cranbury, NJ, USA).
Bone marrow-derived macrophages (BMDM) were differentiated as previously described [28]. To induce M1-like polarization, BMDM were treated with 10 ng/mL LPS for
48 h in the presence or absence of HMB (1 mM).
2.8. Serum Hormones
Circulating hormone levels were analyzed using serum collected in week 10 (before
dietary HMB supplementation and tumor cell injection). Insulin levels were measured
using the Bio-Plex Pro Mouse Diabetes Insulin Single Plex Assay (Bio-Rad, Hercules, CA,
USA) and insulin-like growth factor (IGF)-1 levels were measured using the Millipore MILLIPLEX Rat/Mouse IGF-1 Single Plex Assay (Millipore, Burlington, MA, USA). Analysis
was performed using the Bio-Plex 100 Analysis System (Bio-Rad, Hercules, CA, USA).
2.9. Tumor and Muscle Hematoxylin and Eosin Staining and Immunohistochemistry
Paraffin-embedded tumors and gastrocnemius muscles were cut into 4-µm-thick
sections and processed for either hematoxylin and eosin (H&E) or immunohistochemical
(IHC) staining. The gastrocnemius muscle tissue was cut cross-sectionally to quantify the
thickness of each individual fiber. Staining was performed at the Histology Core Laboratory
at the University of Texas-MD Anderson Cancer Center, Science Park Research Division
(Smithville, TX, USA).
For IHC, antigen retrieval was achieved by microwaving slides with a 10 mM citrate buffer. Nonspecific binding was blocked by treating sections with Biocare blocking
reagent (Biocare Medical, Pacheco, CA, USA) for 30 min at room temperature, followed
by incubation with the primary antibody diluted in a blocking buffer overnight at 4 ◦ C.
The following primary antibodies and dilutions were used: phospho-S6 ribosomal protein
S235/236 (Cell Signaling, 1:100) and Ki-67 (Dako, 1:100).
Images were captured by the Aperio ScanScope XT (Aperio Technologies, Vista, CA,
USA) and staining was quantified using the Aperio ImageScope (Aperio Technologies,
Vista, CA, USA). Automated algorithms were used to determine positive nuclear staining
of Ki-67 and positive cytoplasmic staining of phospho-S6. The percentage of positive
cells (or positive intensity) was obtained with a 10× objective in four different areas of
the PDAC sections. Necrotic sections were excluded. Positive staining was averaged per
treatment group.
2.10. Gene Expression Microarray Analysis
Total RNA was extracted using TRIzol and the RNeasy Kit (Qiagen, Hilden, Germany)
from homogenized tumor samples, and RNA quality was assessed using an Agilent
bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The Affymetrix Mouse Gene
2.1 ST 24-Array plate was used for Study 1, and the Clariom S array was used for all other
samples. Feature selection for PCA and hierarchical clustering was conducted using F or
t statistics.
Gene Set Enrichment Analysis (GSEA) using the Hallmark and GO biological process
curated gene sets in the Molecular Signatures Database (MSigDB) was run with the default
criteria and 1000 permutations [29,30].
Digital cytometry was performed using CIBERSORTx [31], using the mouse reference
signatures obtained from seq-immuCC [32] and 1000 permutations.
2.11. Mass Cytometry
Tumors were dissociated using the Miltenyi mouse tumor dissociation kit, and CD45+
cells were enriched using Percoll differential centrifugation. Live cells were stained using
Cell-ID cisplatin, and Fc receptors were blocked with TruStain FcX (1:100) prior to extracellular staining using the University of North Carolina mass cytometry core antibody
panel. Cells were fixed and permeabilized for intracellular staining of FoxP3 using the
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eBioscience FoxP3 (ThermoFisher Scientific, Waltham, MA, US) staining buffer set. Finally,
cells were intercalated with iridium overnight. Live CD45+ single cells were gated using
Cytobank software (version 9.0, Beckman Coulter, Brea, CA, USA) and then analyzed in R
as previously described [33]. Briefly, following hyperbolic inverse sine transformation, a
self-organizing map was built, and consensus clustering was performed. Over-clustered
clusters were collapsed manually and visualized by tSNE plots. The differential abundance
of each cell type and the differential expression of each marker with each cell type was
determined by a generalized linear mixed logistic model.
2.12. Quantitative RT-PCR
RNA was isolated from differentiated C2C12 myotubes using the E.Z.N.A. total RNA
extraction kit (Omega Bio-Tek, Norcross, GA, USA). Total RNA was reverse-transcribed to
cDNA using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific,
Waltham, MA, US). Gene expression was normalized to the housekeeping gene ß-actin.
Relative differences in gene expression were analyzed using the 2-∆∆CT method. All primers
used are listed in Table S1.
2.13. Muscle Fiber Size
Cross-sectional images of H&E-stained gastrocnemius muscle were analyzed using Fiji
(ImageJ Version 1.53n from the NIH). Prior to analysis, the Advanced Weka Segmentation
classifier included in Fiji was trained by manually marking regions of the small and dark
slow-twitch fibers, the large and light fast-twitch fibers, and the slide background [34].
Muscle fiber size was determined using the minimal Feret’s diameter [35]. Randomly
selected slides (n = 6 mice/group), with 100–400 randomly selected muscle fibers per
slide, were analyzed. The minimal Feret’s diameters of each fiber were averaged for each
treatment group.
2.14. Western Blots
Cells were homogenized in a radioimmunoprecipitation (RIPA) buffer with protease
and phosphatase inhibitors and incubated on ice for 30 min. Samples were then centrifuged
at 16,000 RCF for 15 min at 4 ◦ C, and the supernatant was transferred to a new tube.
Protein lysates were resolved using a 4–16% gradient of polyacrylamide gels and
transferred to nitrocellulose membranes (Sigma, St. Louis, MO, USA). The following
primary antibodies and dilutions were used: myosin heavy chain (1:1000; R&D Systems,
Minneapolis, MN, USA), phospho-p65S536 (1:1000; Cell Signaling Technology, Danvers,
MA, USA), p65 (1:1000; Cell Signaling Technology, Danvers, MA, USA), ß-actin (1:10,000;
Santa Cruz, Dallas, TX, USA), α-tubulin (1:10,000; Santa Cruz, Dallas, TX, USA), and
histone H3 (1:1000; Cell Signaling Technology, Danvers, MA, USA). Membranes were
incubated for 1 h at room temperature in species-specific secondary antibodies (LI-COR)
diluted 1:5000 in 5% BSA in TBS-T.
Membranes were scanned and densitometry was assessed using the Odyssey infrared
fluorescent imaging system using LI-COR software (version 5.2, LI-COR, Lincoln, NE,
USA). Raw values were compared between groups only if samples were on the same
membrane. Raw values normalized to loading control levels were used to calculate the
relative protein levels.
2.15. Nuclear and Cytoplasmic Fractionation of C2C12 Myotubes
To generate nuclear and cytoplasm-enriched fractions, 5 × 106 C2C12 myotubes were
incubated in a hypotonic fractionation buffer containing 10 mM HEPES (pH 7.4), 10 mM
KCl, 1 mM MgCl2, 1 mM EDTA, 1 mM EDGA, 1 mM DTT, and protease and phosphatase
inhibitors on ice for 20 min. Cells were then sheared by passing the solution 5 times
through a 17-gauge needle and then incubating them on ice for an additional 10 min.
The cytoplasmic fraction was obtained by centrifuging the solution at 710 RCF for 5 min
and retaining the supernatant. The nuclear fraction was then washed with a hypotonic
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fractionation buffer, cycling it through a 15-gauge needle 10 times. The nuclear fraction
was centrifuged at 20,000 RCF for 5 min and the pellet was lysed in a RIPA lysis buffer
and sonicated. Histone H3 and α-tubulin were used as purity controls for the nuclear and
cytoplasmic fractions, respectively.
2.16. Statistical Analyses
Statistical analyses were conducted using GraphPad Prism (GraphPad Software 9.0.0,
San Diego, CA, USA). Comparisons between the two groups were analyzed using unpaired, two-tailed t-tests. Comparisons among more than two groups were analyzed using
one-way ANOVA. Associations between HMB treatment and muscle fiber size and CD3
staining were determined by two-way ANOVA. Principal components analysis (PCA) and
hierarchical clustering was performed using R (version 4.0.2, R Core Team, Vienna, Austria).
3. Results
3.1. DIO Increases Bodyweight and Circulating Glucose, Insulin, and IGF-1 Levels
To determine whether HMB alters obesity-exacerbated PDAC tumor growth, we
fed male C57BL/6 mice the control diet (10% kcal fat) or a high-fat DIO diet (60% kcal
fat) to promote obesity. Following 10 weeks of the diet treatment, we confirmed that
mice had achieved the metabolic characteristics expected of DIO. Relative to the control
mice, DIO mice had significantly greater bodyweight, fasting blood glucose, and serum
levels of insulin and IGF-1 (Figure S1A–D). Subsequently, mice were randomized to either
continue on their respective diets or receive the same diets with HMB supplementation
(control + HMB and DIO + HMB), and also received PDAC tumor injections. HMB
supplementation did not alter terminal bodyweight in either diet group (Figure S1E).
3.2. HMB Supplementation Reduces Transplanted PDAC Growth in DIO Mice Independent of
Gemcitabine Treatment, Glucose Levels, and mTOR Activation
DIO mice had an increased tumor volume relative to the control mice (Figure 1A,B).
DIO + HMB mice had a reduced tumor volume relative to DIO mice; however, the tumor
volume in control + HMB mice was not altered relative to that in control mice.
When treated with gemcitabine (50 mg/kg every third day), a common PDAC
chemotherapeutic agent, DIO mice continued to have an elevated tumor volume compared with control mice. HMB supplementation significantly reduced tumor size in DIO
mice such that tumor mass was not different than that of the unsupplemented control
(Figure 1C,D). HMB supplementation did not alter blood glucose in either lean or obese
mice (Figure S2A). Tumoral Ki-67 expression, a marker of proliferation, was increased in
tumors from DIO mice relative to tumors from control mice, while tumors from the DIO +
HMB mice displayed Ki-67 expression levels intermediate to the control and DIO groups
(Figure S2B). However, gemcitabine treatment did not affect Ki-67 expression (Figure S2C).
Given that HMB indirectly promotes mTOR activation via a number of mechanisms [36],
we assessed tumor mTOR activity. HMB did not alter mTOR activity, as reflected by the
extent of S6 phosphorylation in control and DIO mice, irrespective of gemcitabine treatment
(Figure S2D,E).
3.3. HMB Partially Reverses DIO-Associated Changes in Gene Expression in the Tumor
Microenvironment
We performed microarray transcriptomic analysis on tumors from control and DIO
mice with and without HMB supplementation. Principal component analysis and hierarchical clustering of our transcriptomic data, following feature selection using differential
gene expression analysis, revealed a clear separation in gene expression in tumors from
control and DIO mice, as well as separation between tumors from the HMB-treated and
untreated groups (Figure 1E,F).
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We next utilized GSEA to stratify differential gene expression by physiological processes, using the curated Hallmark gene sets [30]. Normalized enrichment scores and the
associated FDRq values for the binary comparisons (control vs. control + HMB, control
vs. DIO, control vs. DIO + HMB, and DIO vs. DIO + HMB) are listed in Table S2. The
GSEA analysis comparing tumors from control and DIO mice revealed that DIO modulated numerous cancer-associated pathways, including hypoxia, KRAS signaling, and the
epithelial-to-mesenchymal transition (EMT), as well as one immune-related gene set. Control + HMB mice, relative to the unsupplemented control, increased three immune-related
gene sets as well as several other gene sets, including cholesterol metabolism and KRAS
signaling. The comparison of control and DIO + HMB mice resembled the comparison of
the control with either factor in isolation, with enrichment of six out of a total of seven
available immune-related gene sets (Figure 1G). The tumoral sensitivity of immune-related
pathways to HMB treatment was confirmed in the comparison of DIO vs. DIO + HMB
mice, in which allograft rejection was the only gene set enriched in tumors from HMB
treated mice (Table S2).
We next analyzed our transcriptomic data using GO biological process gene sets using
the same binary comparisons. Several hundred gene sets were differentially enriched
(Table S2). To reduce redundancy between these gene sets [37], we mapped the resulting
data as enrichment maps and clustered them by gene set overlap. In agreement with our
initial Hallmark gene sets, tumors from DIO mice were enriched for gene sets relating to
prostaglandin signaling and metabolism relative to the control (Figure 2A). Suppression of
olfactory signaling by HMB was the only enriched cluster detected when contrasting control
vs. control + HMB tumors (Figure 2B). The overwhelming majority of gene sets and clusters
enriched in DIO + HMB tumors, when compared with DIO tumors, were immune-related,
and were all enriched in the HMB-supplemented group (Figure 2C). The comparison of
control vs. DIO + HMB mice indicated that >100 gene sets, many immune- or metabolismrelated (Table S2), were enriched in DIO + HMB mice (Figure 2D). We also stained tumor
sections for CD3 to determine tumor CD3+ T cell abundance using CD3 IHC. While CD3+ T
cell abundance was not different among groups, a two-way ANOVA indicated a significant
positive association between HMB and CD3+ T cell numbers (Figure 2E).
3.4. HMB Supplementation Promotes a Response to Anti-PD1 Immune Checkpoint Inhibition
Since PDAC has thus far proven unresponsive to available immunotherapies [1,38],
we hypothesized that HMB would promote a response in these tumors, similar to its effects
in DIO mice. Hence, we subcutaneously injected Panc02 cells into mice fed a control
diet (AIN-93G) with (control + HMB) or without (control) 1% HMB supplementation.
Two weeks following tumor injection, we treated these mice with or without anti-PD1
immunotherapy (200 µg/mouse every third day). We assessed the toxicity of anti-PD1 or
the combination of anti-PD1 + HMB via bodyweight measurements but did not observe
any differences among groups (Figure 3A). Neither HMB nor anti-PD1 alone altered tumor
mass. However, the combination of anti-PD1 + HMB resulted in a reduced tumor burden
relative to the anti-PD1-only group (Figure 3B,C).
We next used GSEA to determine pathway activation within the tumors’ transcriptomic data. All enrichment scores and associated FDRq values are listed in Table S3.
The comparison of anti-PD1 vs. control indicated modest activation of immunerelated gene sets (four of seven), along with limited induction of other cellular metabolic or
signaling responses (Figure 3D). The comparison of control vs. HMB indicated once again
that HMB promoted the activation of various cellular signaling and metabolic pathways,
including estrogen signaling and fatty acid metabolism. In contrast to our previous finding
of the modest activation of immune-related gene sets, we observed the suppression of three
of seven immune-related gene sets following HMB treatment. However, the comparison
of control vs. anti-PD1 + HMB indicated robust activation of anti-tumor immunity (six
of seven immune-related gene sets), with limited activation of other pathways. Digital
cytometry using CIBERSORTx revealed no difference in the resting NK cell population but
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an increased number of activated NK cells in anti-PD1 + HMB compared with the control
(Figure 3E,F). Further, M0-like and M1-like macrophage populations were not altered;
9 of 20
however, M2-like macrophage abundance was reduced in both HMB and anti-PD1 + HMB
compared with the control (Figure 3G–I).
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Figure 3. (A) Body mass of mice supplemented with or without HMB and treated with or without anti-PD1 immunother-
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are considered significant if p < 0.05 (* p < 0.05, ** p < 0.01).

Cancers 2021, 13, 6359

Cancers 2021, 13, 6359

11 of 19

Once again, to gain a more granular insight into pathways activated by HMB, anti-PD1,
or the combination of both treatments, we applied GSEA using the GO biological process
gene sets, followed by enrichment mapping. All enrichment scores and the associated
FDRq values are listed in Table S3. This approach confirmed that anti-PD1 alone compared
with the control promoted limited pathway alteration (Figure 4A). HMB supplementation
alone, compared with the control, promoted the activation of numerous gene sets and gene
set clusters regulating differentiation, signaling, and metabolism; however, we did not
observe the activation of any immune-related gene set clusters (Figure 4B). A comparison
of anti-PD1 vs. anti-PD1 + HMB confirmed that HMB promotes the activation of immuneand muscle-related gene sets (Figure 4C). The combination of anti-PD1 + HMB, compared
12 of 20
with the control, promoted the activation of ~180 gene sets, which clustered into numerous
immune- and metabolic-related pathways (Figure 4D).
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3.5. HMB Supplementation Promotes M1-Like Macrophage Activation

ncers 2021, 13, 6359

To determine whether HMB supplementation alters the tumor immune profile, we
performed mass cytometry on tumors from control and HMB-supplemented mice. The
distribution of cell populations was visualized using tSNE plots following clustering by
FlowSOM (Figure 5A). Of the nine identified cell populations, three were differentially
abundant between the control and HMB supplementation groups: neutrophils (Figure 5B),
CD4+ T cells (Figure 5C), and tumor-associated macrophages (Figure 5D). We next assessed
whether HMB supplementation altered TAM polarization in vivo. TAM expression of the
13 of 20
M1-like marker CD38 was increased by HMB supplementation (Figure 5E), and expression
of the M2-like marker Arg1 was reduced by HMB supplementation (Figure 5F).
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in TAMs from tumors from control or HMB-supplemented mice (n = 3–4/group). Differences be(n = 3–4/group). Differences between groups considered significant if p < 0.05 (* p < 0.05, ** p < 0.01).
tween groups considered significant if p < 0.05 (* p < 0.05, ** p < 0.01).

We sought to directly test whether HMB promotes putatively antitumor M1-like
macrophage polarization in vitro. M1-like macrophages were differentiated from bone
marrow-derived macrophages using 10 ng/mL LPS for 48 h in the presence or absence of
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We sought to directly test whether HMB promotes putatively antitumor M1-like
macrophage polarization in vitro. M1-like macrophages were differentiated from bone
marrow-derived macrophages using 10 ng/mL LPS for 48 h in the presence or absence of
HMB. M0 bone marrow-derived macrophages were treated with HMB for 48 h. Principal
component analysis of the transcriptomic data revealed partial separation between nonHMB-treated versus HMB-treated M0 and M1 macrophages (Figure 6A). GSEA analysis
14 of 20
was conducted using the Hallmark gene sets to identify the pathways induced by HMB
treatment in either M0- or M1-like macrophages. GSEA enrichments in the comparison
between M0- and M1-like macrophages were used to identify M1-like pathway activation.
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Analysis of pathway activation by GSEA using the Hallmark gene sets revealed that
HMB supplementation suppressed proinflammatory signaling while promoting oxidative
phosphorylation (Figure S3). To further interrogate these data, we the GSEA GO bioprocess gene sets and visualized the results using enrichment mapping. In accordance with
the Hallmark gene set analysis, the GO bioprocess gene sets also revealed that HMB was
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Having established that HMB protects muscle mass and suppresses inflammation in
vivo (including TNFα signaling), we sought to determine whether HMB could directly
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Analysis of pathway activation by GSEA using the Hallmark gene sets revealed that
HMB supplementation suppressed proinflammatory signaling while promoting oxidative
phosphorylation (Figure S3). To further interrogate these data, we the GSEA GO bioprocess
gene sets and visualized the results using enrichment mapping. In accordance with the
Hallmark gene set analysis, the GO bioprocess gene sets also revealed that HMB was
associated with the suppression of numerous inflammatory processes, as well as promotion
of mitochondrial translation (Figure 7D; Table S5).
Having established that HMB protects muscle mass and suppresses inflammation
in vivo (including TNFα signaling), we sought to determine whether HMB could directly
antagonize pro-inflammatory signaling through NF-κB in C2C12 myotubes in vitro. To test
this, we differentiated C2C12 murine muscle cells, as confirmed by myosin heavy chain
expression, and subsequently treated the myotubes with 10 ng/mL TNFα in serum-free
media with or without 4 mM HMB for 18 h. To confirm a reduction of NF-κB activity we
performed nuclear cytosolic fractionation, employing histone H3 and α-tubulin as purity
controls for nuclear and cytoplasmic fractions, respectively. Nuclear localization of p65
following TNFα treatment was reduced, indicating significant inhibition of NF-κB activity
(Figure 7E,F, Figure S4). Simultaneously, gene expression of Myogenic Differentiation 1
(Myod, a myogenic transcription factor suppressed by NF-κB [39]), and Myosin Heavy
Chain 7 (Myh7, terminal muscle differentiation marker) was upregulated as determined by
qPCR (Figure 7G,H).
4. Discussion
Our findings demonstrate that dietary HMB supplementation decreases in vivo growth
of PDAC in DIO mice, promotes antitumor immunity in DIO mice, and improves immunotherapy response in control mice. More specifically, we show that HMB supplementation not only remodels the pro-tumorigenic microenvironment associated with DIO
to promote antitumor immunity but also synergizes with anti-PD1 immunotherapy and
promotes M1-like polarization of macrophages. Our results also indicate that HMB antagonizes inflammatory signaling through NF-κB in myotubes in vitro and muscle in vivo.
Taken together these data suggest that HMB supplementation may promote antitumor
immunity while reducing inflammatory signaling in muscle. These findings are important given the current dearth of effective PDAC therapy in the clinic, the prevalence of
muscle wasting in patients with PDAC, and the well-established anabolic utility of HMB
supplementation [40].
The obesity epidemic, the rising prevalence of obesity-associated PDAC, and the
increasing proportion of PDAC patients that are obese at the start of therapy lend considerable urgency to better understanding obesity and PDAC [8]. Obesity [14–16] and
maintenance of muscle mass [6,41,42] both independently predict a favorable response
to immune checkpoint inhibition therapy. Separately, sarcopenic obesity is linked with
increased morbidity and mortality in patients with PDAC due at least in part to its association with cancer-associated cachexia [10]. Thus, obesity is a critical determinant of therapy
response in PDAC. Here we have identified in our preclinical studies that HMB supplementation may be an effective, low-cost intervention that promotes antitumor immunity
and preserves muscle mass in PDAC.
HMB supplementation exerted differential effects on muscle versus tumor. In the
muscle, HMB supplementation promoted increased muscle fiber size and suppressed
inflammatory signaling. Additionally, HMB antagonized NF-κB signaling and promoted
myogenic gene expression in vitro. These data are consistent with a muscle protective
role for HMB mediated in part via antagonizing inflammatory signaling. TNFα signaling
through NF-kB is a pleotropic regulator of the immunotherapy response [23]. In muscle,
NF-κB leads to muscle atrophy via increased protein degradation [25]. Inhibition of NF-κB
prevents cancer-induced muscle atrophy [26]. NF-kB signaling is highly activated in an
obese environment [43], which may explain why patients with sarcopenic obesity often
have enhanced tumor growth coupled with muscle loss. Indeed, in a rat model of breast
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cancer, HMB decreased inflammatory signaling within cancer cells and protected against
cachexia [20]. In our tumor-bearing control-fed mice, HMB had no effect on tumor size
or tumor cell proliferation, and had limited effects on the tumor transcriptome. However,
HMB significantly decreased the tumor size in DIO mice and DIO mice treated with
gemcitabine. These HMB-mediated effects were independent of blood glucose levels or
tumor mTOR activation. This contrasts with leucine, of which HMB is a metabolite, which
promotes tumor growth and mTOR activation in PDAC [44].
To determine potential mediators of the antitumor effects of HMB, we analyzed
the tumor transcriptome. GSEA revealed that the combination of HMB with the proinflammatory stimuli from either DIO or anti-PD1 promoted effective antitumor immunity,
including increased T cells within tumors following HMB supplementation. HMB is also
known to promote in vitro phagocytic function and respiratory burst formation in chicken
macrophages [21], goat monocytes, and goat granulocytes [22]. In this study, we identified antitumor M1-like macrophage polarization in vivo and in vitro following HMB
supplementation alone or in combination with anti-PD1. Immunosuppressive M2-like
macrophages promote tumor growth via several mechanisms [45]. Thus, the finding
that HMB supplementation promotes antitumor polarization of macrophages in vitro and
in vivo suggests that HMB may promote the metabolic reprogramming of macrophages.
Although our PDAC transplant model provides insights into how HMB supplementation effects tumor growth, it cannot provide information with respect to tumor development.
An additional limitation of our PDAC transplant model is that it does not induce cancerassociated cachexia. However, there are other well-established cachexia mouse models in
which HMB has been demonstrated to prevent cancer-associated cachexia [46,47]. HMB has
been shown to reduce cachexia, with a concomitant decrease in NF-κB, in a subcutaneous
injection model of Walker-256 breast cancer cells in Sprague-Dawley rats [20]. Similarly,
in an intraperitoneal injection model of Yoshida AH-130 ascites hepatoma cells in Wistar
rats, HMB was again found to reduce cachexia, and this observation was associated with
mTOR activation [47]. Thus, while our PDAC model does not induce cachexia, the muscleprotective effects we observed are consistent with the findings in other well-characterized
cancer cachexia models.
5. Conclusions
This report established that: (1) HMB is associated with increased muscle fiber size
and a reduction in muscle inflammation in control and DIO mice; (2) obesity significantly increases Panc02 tumor growth, which is antagonized by HMB; (3) gene expression profiling
and immunohistochemistry indicate that HMB promotes antitumor immunity in control
and DIO mice; (4) HMB synergizes with anti-PD1 immunotherapy in PDAC to elicit antitumor immunity; and (5) HMB promotes proinflammatory macrophage activation. These
preclinical findings suggest that HMB has promising muscle-sparing, immune-enhancing,
and antitumor activities against PDAC in the context of obesity and anti-PD1 immunotherapy. Given the well-established and minimal side-effect profile of HMB in cancer patient
populations, this work positions HMB as a potential adjuvant to PDAC therapy.
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